Summary
BAY m1099 (a 1-deoxynojirimycin derivative) is a glucose analogue which is an α-glucosidase inhibitor. Its effects on post-prandial blood glucose and insulin levels was compared with a placebo in 12 healthy male volunteers (6 Blacks and 6 Whites). It produced a similar, significant depression of post-prandial blood glucose and insulin leveles when the groups were assessed separately and when the data were pooled. Although blood insulin levels in Whites were higher than in Blacks, as previously reported, the difference was not statistically significant and did not appear to influence the response to the drug. BAY 1099 produced no objective or subjective untoward effects and appears to warrant further investigation as an adjuvant to dietary control of diabetes mellitus.
Similar content being viewed by others
References
Jenkins DJA, Leeds AR, Gassul MA et al. (1977) Decrease in post-prandial insulin and glucose concentrations by guar and pectin. Ann Int Med 86: 20–23
Walton RJ, Sheriff IT, Noy GA et al. (1979) Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidase inhibitor. Br Med J 1: 220–221
Meyer BH, Müller FO, Grigoleit HG et al. (1983) Inhibition of starch absorption by tendamisate (an alpha-amylase inactivator). S Afr Med J 64: 248–285
Schmidt DD, Frommer W, Müller L et al. (1979) Glucosidase-Inhibitoren aus Bazillen. Naturwissenschaften 66: 584–585
Saunier B, Kilker RD, Tkacz JS et al. (1982) Inhibition of N-linked complex oligosaccharide synthesis by 1-deoxynojirimycin, an inhibitor of processing. J Biol Chem 23: 14155–14161
Rubenstein AH, Saftel HC, Miller K et al. (1969) Metabolic response to oral glucose in healthy South African White, Indian and African subjects. Br Med J 1: 748–751
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Joubert, P.H., Venter, C.P., Joubert, H.F. et al. The effect of a 1-deoxynojirimycin derivative on post-prandial blood glucose and insulin levels in healthy black and white volunteers. Eur J Clin Pharmacol 28, 705–708 (1985). https://doi.org/10.1007/BF00607920
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00607920